Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
← catalyst calendarNCT06925685 · readout ≤ 4,548 d
Sponsored by Allogene Therapeutics (industry) · ALLO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
50estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-31 | actual | When the study began enrolling |
| Primary completion | Jan 2039 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2039 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hematologic Malignancies
- Solid Tumors
Primary outcomes
what the primary-completion date above is the date OFIncidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs
measured Up to 15 years post treatment with allogeneic CAR T-cell product
Overall survival (OS)
measured Up to 15 years post treatment with allogeneic CAR T cell product
Presence of replication competent lentivirus (RCL) in blood
measured Up to 15 years post treatment with allogeneic CAR T cell product
Permalink · ALLO's whole pipeline · Catalyst calendar · Every registered study · What changed